دورية أكاديمية
أعرض في EDS

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.

التفاصيل البيبلوغرافية
العنوان: Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.
المؤلفون: Lesovaya EA; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.; Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, 9 Vysokovol'tnaya St., Ryazan 390026, Russia.; Laboratory of Single Cell Biology, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia., Fetisov TI; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia., Bokhyan BY; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia., Maksimova VP; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia., Kulikov EP; Faculty of Oncology, I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, 9 Vysokovol'tnaya St., Ryazan 390026, Russia., Belitsky GA; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia., Kirsanov KI; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.; Laboratory of Single Cell Biology, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia., Yakubovskaya MG; N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia, 24 Kashirskoe Shosse, Moscow 115478, Russia.; Laboratory of Single Cell Biology, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia.
المصدر: Cancers [Cancers (Basel)] 2024 Jan 08; Vol. 16 (2). Date of Electronic Publication: 2024 Jan 08.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Liposarcoma (LPS) is one of the most common adult soft-tissue sarcomas (STS), characterized by a high diversity of histopathological features as well as to a lesser extent by a spectrum of molecular abnormalities. Current targeted therapies for STS do not include a wide range of drugs and surgical resection is the mainstay of treatment for localized disease in all subtypes, while many LPS patients initially present with or ultimately progress to advanced disease that is either unresectable, metastatic or both. The understanding of the molecular characteristics of liposarcoma subtypes is becoming an important option for the detection of new potential targets and development novel, biology-driven therapies for this disease. Innovative therapies have been introduced and they are currently part of preclinical and clinical studies. In this review, we provide an analysis of the molecular genetics of liposarcoma followed by a discussion of the specific epigenetic changes in these malignancies. Then, we summarize the peculiarities of the key signaling cascades involved in the pathogenesis of the disease and possible novel therapeutic approaches based on a better understanding of subtype-specific disease biology. Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4 /6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.
References: Cancer. 2011 Dec 1;117(23):5359-69. (PMID: 21598240)
Int J Cancer. 2014 Jul 15;135(2):348-61. (PMID: 24375455)
Cancer Res. 2011 Apr 1;71(7):2697-705. (PMID: 21335544)
Am J Cancer Res. 2016 Jan 15;6(2):544-52. (PMID: 27186423)
Nat Commun. 2019 Dec 12;10(1):5683. (PMID: 31831742)
Am J Surg Pathol. 2004 Oct;28(10):1257-67. (PMID: 15371941)
Cancer. 2012 Feb 1;118(3):770-6. (PMID: 21751200)
Cancer. 2017 Dec 1;123(23):4640-4647. (PMID: 28832986)
Cancer Discov. 2011 Dec;1(7):555-6. (PMID: 22586679)
Mod Pathol. 2014 Sep;27(9):1238-45. (PMID: 24457462)
Cancers (Basel). 2021 Jun 18;13(12):. (PMID: 34207401)
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70. (PMID: 25392179)
EMBO Rep. 2019 May;20(5):. (PMID: 30962207)
J Clin Oncol. 2018 Jan 10;36(2):151-159. (PMID: 29220294)
Diagn Cytopathol. 2012 Dec;40(12):1122-31. (PMID: 21932353)
FEBS Lett. 2017 Sep;591(18):2905-2918. (PMID: 28670683)
Am J Pathol. 2013 Apr;182(4):1400-11. (PMID: 23416162)
Diagn Pathol. 2021 Apr 20;16(1):32. (PMID: 33879215)
Cancers (Basel). 2019 Aug 14;11(8):. (PMID: 31416195)
Cell Mol Life Sci. 2016 Oct;73(19):3711-8. (PMID: 27173057)
Mod Pathol. 2015 Nov;28(11):1404-14. (PMID: 26336885)
Neuro Oncol. 2019 Aug 5;21(8):1005-1015. (PMID: 30976795)
J Hematol Oncol. 2017 Jun 19;10(1):123. (PMID: 28629371)
Cancer Res. 2013 Feb 15;73(4):1298-307. (PMID: 23393200)
Virchows Arch. 2012 Jul;461(1):67-78. (PMID: 22678079)
Cancer. 2012 Nov 1;118(21):5403-13. (PMID: 22570147)
Genes Chromosomes Cancer. 2011 Nov;50(11):896-907. (PMID: 21910158)
Ann Surg Oncol. 2008 Jun;15(6):1585-93. (PMID: 18398663)
Surg Oncol Clin N Am. 2022 Jul;31(3):321-340. (PMID: 35715137)
Histopathology. 2014 Jan;64(1):38-52. (PMID: 24118009)
Cancer Res. 1990 Dec 15;50(24):7902-7. (PMID: 2253229)
Clin Cancer Res. 2017 Oct 15;23(20):6227-6238. (PMID: 28637688)
Neoplasia. 2019 Aug;21(8):740-751. (PMID: 31220736)
Oncogenesis. 2016 Feb 22;5:e199. (PMID: 26900951)
Oncol Lett. 2021 Aug;22(2):623. (PMID: 34285721)
Mod Pathol. 2021 Nov;34(11):2043-2049. (PMID: 34168281)
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. (PMID: 10097144)
Oncogene. 1994 Oct;9(10):3087-97. (PMID: 8084618)
Curr Opin Obstet Gynecol. 2016 Feb;28(1):42-8. (PMID: 26642065)
Oncogene. 2009 Jan 15;28(2):270-8. (PMID: 18850010)
Stem Cells. 2011 Jan;29(1):32-45. (PMID: 21280157)
Nature. 1993 Jun 17;363(6430):640-4. (PMID: 8510758)
Nature. 2009 Mar 5;458(7234):92-6. (PMID: 19118383)
EMBO Mol Med. 2019 May;11(5):. (PMID: 30898787)
Pathology. 2008 Oct;40(6):547-52. (PMID: 18752119)
Nat Rev Cancer. 2020 Oct;20(10):608-623. (PMID: 32782366)
Lab Invest. 2018 Jul;98(7):957-967. (PMID: 29588491)
Ann Surg. 2004 Oct;240(4):686-95; discussion 695-7. (PMID: 15383796)
Pathol Int. 2003 Oct;53(10):671-9. (PMID: 14516317)
Biochem Biophys Res Commun. 2012 Oct 19;427(2):355-60. (PMID: 22995304)
Pharmacol Res. 2022 Nov;185:106462. (PMID: 36167276)
Cancer Res. 2023 May 2;83(9):1517-1530. (PMID: 36847778)
EClinicalMedicine. 2023 Sep 21;64:102240. (PMID: 37767191)
Int J Mol Sci. 2023 May 31;24(11):. (PMID: 37298520)
Future Oncol. 2014 Jun;10(8):1373-86. (PMID: 25052748)
PLoS One. 2008 Sep 11;3(9):e3179. (PMID: 18784837)
Oncogenesis. 2022 Apr 22;11(1):20. (PMID: 35459264)
Cancer Discov. 2023 Aug 4;13(8):1802-1813. (PMID: 37269344)
Sci Rep. 2019 Mar 1;9(1):3197. (PMID: 30824765)
Cell. 2017 Nov 2;171(4):950-965.e28. (PMID: 29100075)
Mod Pathol. 2009 Feb;22(2):223-31. (PMID: 18820664)
PLoS One. 2012;7(8):e43664. (PMID: 22928012)
Int J Cancer. 2006 Nov 15;119(10):2347-52. (PMID: 16858687)
Clin Cancer Res. 2023 May 1;29(9):1708-1718. (PMID: 37058010)
Virchows Arch. 2010 Feb;456(2):201-17. (PMID: 20217954)
Mod Pathol. 2010 Oct;23(10):1307-15. (PMID: 20581806)
Cancer Sci. 2022 Mar;113(3):1078-1089. (PMID: 34971481)
JAMA Oncol. 2016 Feb;2(2):253-60. (PMID: 26633733)
Hum Pathol. 2016 Apr;50:15-23. (PMID: 26997434)
Cancer. 2007 Jun 15;109(12):2522-31. (PMID: 17510918)
Surg Pathol Clin. 2016 Sep;9(3):457-73. (PMID: 27523972)
Mol Cell. 2022 May 5;82(9):1737-1750.e8. (PMID: 35390276)
Ann Surg. 2006 Sep;244(3):381-91. (PMID: 16926564)
Sci Signal. 2013 Sep 24;6(294):ra85. (PMID: 24065146)
Drug Resist Updat. 2011 Feb;14(1):52-66. (PMID: 21169051)
Cancer Res. 2012 Apr 1;72(7):1751-62. (PMID: 22350414)
Cancer Res. 2011 Sep 1;71(17):5659-69. (PMID: 21693658)
Eur J Cancer. 2005 Dec;41(18):2853-60. (PMID: 16289617)
EMBO Mol Med. 2019 May;11(5):. (PMID: 30979710)
Oncotarget. 2015 Mar 10;6(7):4773-89. (PMID: 25749382)
Cancer Biomark. 2018;22(2):199-207. (PMID: 29689704)
Oncotarget. 2017 Feb 7;8(6):9108-9122. (PMID: 27791200)
Gynecol Oncol. 2010 Jun;117(3):417-22. (PMID: 20378157)
Ann Surg Oncol. 2011 Dec;18(13):3762-70. (PMID: 21614627)
Surg Oncol Clin N Am. 2016 Oct;25(4):761-73. (PMID: 27591497)
Pathologica. 2021 Apr;113(2):70-84. (PMID: 33179614)
Clin Cancer Res. 2022 Dec 1;28(23):5058-5065. (PMID: 36129471)
Int J Mol Sci. 2022 Jul 15;23(14):. (PMID: 35887151)
Oncologist. 2020 Nov;25(11):e1655-e1662. (PMID: 32701199)
Oncotarget. 2015 Apr 30;6(12):10510-20. (PMID: 25888633)
Onco Targets Ther. 2017 Jun 16;10:3017-3027. (PMID: 28670134)
Genes Chromosomes Cancer. 2012 Nov;51(11):982-96. (PMID: 22811003)
Cancers (Basel). 2020 Oct 20;12(10):. (PMID: 33092134)
BMC Cancer. 2010 Jun 01;10:249. (PMID: 20515481)
J Clin Oncol. 2022 Aug 1;40(22):2479-2490. (PMID: 35394800)
Mod Pathol. 2015 Aug;28(8):1064-73. (PMID: 26022452)
Oncotarget. 2015 Dec 15;6(40):42429-44. (PMID: 26643872)
BMC Cancer. 2022 Mar 21;22(1):300. (PMID: 35313831)
Cancer Discov. 2011 Dec;1(7):587-97. (PMID: 22328974)
Nat Rev Mol Cell Biol. 2003 Jun;4(6):479-89. (PMID: 12778127)
JAMA Oncol. 2016 Jul 1;2(7):937-40. (PMID: 27124835)
Oncotarget. 2015 Apr 30;6(12):10586-91. (PMID: 25888631)
Cancer Sci. 2022 Jun;113(6):1984-1998. (PMID: 35307915)
Medicine (Baltimore). 2016 Aug;95(31):e4368. (PMID: 27495042)
Clin Cancer Res. 2018 Nov 1;24(21):5233-5238. (PMID: 29895706)
Int J Cancer. 2011 Oct 15;129(8):1963-9. (PMID: 21154746)
Curr Opin Oncol. 2022 Jul 1;34(4):354-361. (PMID: 35730501)
Front Oncol. 2023 Mar 09;13:1122508. (PMID: 36969064)
Front Oncol. 2018 Dec 12;8:608. (PMID: 30631751)
Hum Pathol. 2016 Sep;55:143-50. (PMID: 27237367)
J Cancer. 2018 Jul 16;9(16):2807-2816. (PMID: 30123349)
Br J Cancer. 2003 Oct 20;89(8):1409-12. (PMID: 14562008)
Crit Rev Oncol Hematol. 2020 Sep;153:103029. (PMID: 32593094)
Oncotarget. 2017 Mar 17;8(33):53968-53977. (PMID: 28903316)
Cancer Res. 2017 Nov 1;77(21):5728-5740. (PMID: 28882999)
Metabolites. 2021 Jan 31;11(2):. (PMID: 33572567)
Expert Rev Clin Pharmacol. 2017 Apr;10(4):361-377. (PMID: 28135854)
Int J Mol Sci. 2023 Apr 10;24(8):. (PMID: 37108172)
Oncogene. 2018 Sep;37(37):5066-5078. (PMID: 29789718)
Cancers (Basel). 2023 Mar 13;15(6):. (PMID: 36980621)
Curr Treat Options Oncol. 2023 Apr;24(4):292-299. (PMID: 36867390)
Front Oncol. 2022 Feb 03;12:816894. (PMID: 35186752)
Cancer Med. 2023 Jun;12(12):13455-13470. (PMID: 37132262)
Cancer Genomics Proteomics. 2021 Nov-Dec;18(6):715-721. (PMID: 34697064)
Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1. (PMID: 14501502)
Biomed Res Int. 2022 Dec 7;2022:1580410. (PMID: 36531655)
Int J Mol Sci. 2018 Feb 18;19(2):. (PMID: 29463038)
Oncotarget. 2016 Aug 23;7(34):54583-54595. (PMID: 27409346)
PLoS One. 2020 Jan 23;15(1):e0228014. (PMID: 31971976)
Oncogenesis. 2023 May 26;12(1):30. (PMID: 37237004)
Oncotarget. 2015 Aug 21;6(24):20215-30. (PMID: 26036639)
Oncogene. 2016 Dec 1;35(48):6177-6188. (PMID: 27157622)
Int J Oncol. 2015 Aug;47(2):429-36. (PMID: 26082006)
Pathol Res Pract. 2009;205(6):386-94. (PMID: 19186005)
Cancer Cell Int. 2018 Jun 26;18:89. (PMID: 29983640)
Lab Invest. 2016 Apr;96(4):481-91. (PMID: 26878133)
Epigenomics. 2011 Dec;3(6):715-32. (PMID: 22126291)
Pathol Int. 2017 Sep;67(9):435-446. (PMID: 28759137)
Gynecol Oncol. 2011 Apr;121(1):174-80. (PMID: 21163514)
Oncotarget. 2016 Mar 29;7(13):16581-92. (PMID: 26918731)
Genome Biol. 2013 Dec 17;14(12):r137. (PMID: 24345474)
Mol Cancer Ther. 2019 Apr;18(4):834-844. (PMID: 30787173)
معلومات مُعتمدة: 23-65-00003 Russian Science Foundation
فهرسة مساهمة: Keywords: dedifferentiated liposarcoma; epigenetic changes; liposarcoma; molecular genetic abnormalities; myxoid pleomorphic liposarcoma; myxoid/round-cell liposarcoma; pleomorphic liposarcoma; targeted therapy; well-differentiated liposarcoma
تواريخ الأحداث: Date Created: 20240123 Latest Revision: 20240128
رمز التحديث: 20240128
مُعرف محوري في PubMed: PMC10813500
DOI: 10.3390/cancers16020271
PMID: 38254762
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16020271